BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
pharmafile | November 27, 2018 | News story | Manufacturing and Production, Research and Development | Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as a maintenance treatment for extensive-stage small cell lung cancer (SCLC) without disease progression following the completion of first-line platinum-based chemotherapy.
Compared to placebo, the manufacturer said that its PD-1 inhibitor/CTLA-4 inhibitor combo failed to improve the Phase 3 trial’s primary endpoint of overall survival compared to placebo. It is not known whether the therapy managed to meet its secondary endpoint of overall survival improvement for Opdivo as a monotherapy.
News of the failure send shares falling by 4%. BMS said that it would be working with investigators on the study to ensure the publication of full results from the study.
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …